William Blair analyst Brandon Vazquez has maintained their bullish stance on ALGN stock, giving a Buy rating on April 29.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Brandon Vazquez has given his Buy rating due to a combination of factors that indicate a positive outlook for Align Tech. The company’s sales and earnings per share have surpassed expectations, and the full-year guidance has been slightly raised despite ongoing macroeconomic challenges. This increase in guidance is attributed to favorable foreign exchange conditions, while the underlying volume growth remains stable, which is seen as a positive sign in the current environment.
Additionally, strong international performance is compensating for some relative weakness in the U.S. market, providing overall stability. The potential for further upside in 2025 is supported by positive developments such as a favorable VAT ruling in the U.K., improving macroeconomic conditions, and the success of new products, which have driven significant growth in the teen segment. However, macroeconomic risks remain a concern, as consumer sentiment can impact results, though current guidance does not suggest this will be an issue in 2025. With the stock trading at 16 times the estimated earnings for 2026, the recommendation to buy is maintained.
According to TipRanks, Vazquez is a 2-star analyst with an average return of -2.8% and a 28.57% success rate. Vazquez covers the Healthcare sector, focusing on stocks such as PROCEPT BioRobotics, Neogen, and Henry Schein.
In another report released on April 29, Mizuho Securities also maintained a Buy rating on the stock with a $245.00 price target.